• Join
  • Login
  • Contact

Search abstracts / presentations

Effectiveness and safety of mepolizumab in the treatment of severe eosinophilic asthma

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-092
  • By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
  • Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, santander, Spain)
    Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
    Mrs Julia Sanchez Gundin, Hospital Pharmacist
    Mrs Victor Fernandez Martinez, Hospital Pharmacist
    Ms Marina Barbara Ramis Barcelo, Hospital Pharmacist
    Mrs Marta Valero Dominguez, Hospital Pharmacist
  • Abstract:

    Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity. IL-5 is the major cytokine responsible for the growth and
    differentiation, recruitment, activation and survival of eosinophils.

    To analyse the effectiveness of mepolizumab in patients..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses